imatinib mesylate has been researched along with Cryoglobulinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alpers, CE; Banas, MC; Becker-Herman, S; Guo, S; Hudkins, KL; Iyoda, M; Kowalewska, J; Liu, G; Meyer-Bahlburg, A; Rawlings, DJ; Wietecha, TA; Ziegler, SF | 1 |
| Fogo, AB; Schulman, G; Wallace, E | 1 |
2 other study(ies) available for imatinib mesylate and Cryoglobulinemia
| Article | Year |
|---|---|
Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis.
Topics: Animals; B-Lymphocytes; Benzamides; Complement C3; Cryoglobulinemia; Cytokines; Female; Glomerulonephritis, Membranoproliferative; Imatinib Mesylate; Lymphocyte Activation; Male; Mice; Mice, Transgenic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thymic Stromal Lymphopoietin | 2009 |
Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis.
Topics: Benzamides; Cryoglobulinemia; Glomerulonephritis, Membranoproliferative; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |